Dr Lalchandani Labs Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Dr Lalchandani Labs Ltd is ₹ 6.96 as of 23 Oct 15:30 . The P/E Ratio of Dr Lalchandani Labs Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Yatharth Hospital & Trauma Care Services Ltd changed from 31.3 on March 2024 to 33.9 on March 2026 . This represents a CAGR of 2.70% over 3 years The Market Cap of Dr Lalchandani Labs Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 3582 crore on March 2024 to ₹ 5946 crore on March 2026 . This represents a CAGR of 18.40% over 3 years The revenue of Dr Lalchandani Labs Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 397.01 crore as compare to the Mar '26 revenue of ₹ 348.67 crore. This represent the growth of 13.86% The ebitda of Dr Lalchandani Labs Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 96.04 crore as compare to the Mar '26 ebitda of ₹ 87.02 crore. This represent the growth of 10.37% The net profit of Dr Lalchandani Labs Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 30.38 crore to ₹ 45.42 crore over 9 quarters. This represents a CAGR of 19.57% The Dividend Payout of Dr Lalchandani Labs Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Yatharth Hospital & Trauma Care Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Dr Lalchandani Labs Ltd

Dr Lalchandani Labs Limited was originally incorporated as Partnership Firm at New Delhi dated 15 September, 2011 in the name of Dr. A Lalchandani Pathology Laboratories.
Thereafter, the Partnership Firm was taken over by M/s Dr Lalchandani Labs Limited on 2nd August, 2017 issued by the Registrar of Companies, Delhi vide agreement dated 31st August, 2017.
The Firm was established by Dr. Arjan Lal Chandani and his son Mr. Mohit Lal Chandani as a Partnership Firm in the name of 'Dr. A Lalchandani Pathology Laboratories' in 2011 and in year 2017, they formed a Company in the name and style M/s Dr Lalchandani Labs Limited and took over the Partnership firm. The Company is a provider of diagnostic and related healthcare tests and services in Delhi/NCR. Through its integrated network, it offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

About Yatharth Hospital & Trauma Care Services Ltd

Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008.
On November 3, 2021, the status converted into a Public Company and name of the Company was changed to Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC. Yatharth Hospitals and Trauma Care Services Limited is a network of super speciality hospitals across Delhi National Capital Region (NCR) and Madhya Pradesh, capitalising on the robust healthcare infrastructure in these regions to serve a wide patient base in need of tertiary care. The Company operate three super specialty hospitals in Delhi NCR, i.e., at Greater Noida, Uttar Pradesh.
The super speciality tertiary care hospital currently operates with 400 beds, including 112 critical care beds and 9 modular operation theatres, among other surgical facilities.

FAQs for the comparison of Dr Lalchandani Labs Ltd and Yatharth Hospital & Trauma Care Services Ltd

Which company has a larger market capitalization, Dr Lalchandani Labs Ltd or Yatharth Hospital & Trauma Care Services Ltd?

Market cap of Dr Lalchandani Labs Ltd is 6 Cr while Market cap of Yatharth Hospital & Trauma Care Services Ltd is 8,978 Cr

What are the key factors driving the stock performance of Dr Lalchandani Labs Ltd and Yatharth Hospital & Trauma Care Services Ltd?

The stock performance of Dr Lalchandani Labs Ltd and Yatharth Hospital & Trauma Care Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Lalchandani Labs Ltd and Yatharth Hospital & Trauma Care Services Ltd?

As of October 25, 2026, the Dr Lalchandani Labs Ltd stock price is INR ₹6.96. On the other hand, Yatharth Hospital & Trauma Care Services Ltd stock price is INR ₹931.85.

How do dividend payouts of Dr Lalchandani Labs Ltd and Yatharth Hospital & Trauma Care Services Ltd compare?

To compare the dividend payouts of Dr Lalchandani Labs Ltd and Yatharth Hospital & Trauma Care Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.